Skip to main content

News

You are here

Xcision Announces Start of Breast Cancer Treatments Using GammaPod™ Stereotactic Radiotherapy System at Leading Italian Hospital

Thursday, April 14, 2022

Xcision Medical Systems, LLC today announced that Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) in Italy recently began treating patients with the GammaPod™ Stereotactic Radiotherapy System, a breast cancer treatment system for women with early-stage disease that provides a full course of treatment in one to five sessions.

Xcision Medical Systems, LLC today announced that Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) in Italy recently began treating patients with the GammaPod™ Stereotactic Radiotherapy System, a breast cancer treatment system for women with early-stage disease that provides a full course of treatment in one to five sessions.

“GammaPod will allow us to revolutionize the management of localized breast cancer,” said Marco Trovò, MD, head of the Radiotherapy Department at ASU FC. “Clinical evidence shows that one to five radiotherapy treatments targeting only the tumor bed are noninferior to conventional radiation delivered to the whole breast over three to seven weeks.”

The GammaPod uses a first-of-its kind breast cup system that immobilizes the affected breast to minimize motion and provides stereotactic localization for treatment planning. This enables clinicians to precisely target the area to be treated and direct highly conformal doses of radiation that fall off sharply to spare surrounding healthy breast tissue, the heart and lungs. During treatment, the dose is dynamically painted to the target as the patient’s breast moves through the point where 25 beams converge to deliver a focal dose of radiation. Additionally, the beams rotate continuously during treatment, which creates thousands of beam angles to improve the uniformity of target coverage.

Read the full release on Cision.